Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs~Exclusion Criteria:~* Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the study period~* Patients who are at a significantly high risk for bleeding or thromboembolism~* Patients who are receiving another antithrombotic therapy and are unable to suspend the therapy~* Patients who have evidence of hepatic function test abnormalities

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SRI 15mg (15 mL/min ≤ CLCR < 20mL/min) (Type: EXPERIMENTAL): Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
- MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min) (Type: EXPERIMENTAL): Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
- Fondaparinux (20 mL/min ≤ CLCR < 30mL/min) (Type: ACTIVE_COMPARATOR): Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
- SRI 15mg (20 mL/min ≤ CLCR < 30mL/min) (Type: EXPERIMENTAL): Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).